중동 호흡기 증후군 치료에 사용한 항바이러스제의 약물이상반응 발현양상 분석
Evaluation of Adverse Drug Reaction of Antiviral Therapy for Middle East Respiratory Syndrome Coronavirus Infection
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : Treatment experiences with antiviral agents against MERS-CoV (Middle East Respiratory Syndrome Coronavirus) infection are limited, and there is lack of information regarding adverse drug reactions (ADRs) in this patient group. In 2015, we evaluated the ADRs of antiviral treatment against MERS-CoV infections in one tertiary teaching hospital in South Korea. Methods : Between May 20th and July 20th 2015, a retrospective chart review was conducted to evaluate any ADRs. We focused on three antiviral agents: ribavirin, peginterferon alpha2a and lopinavir/ritonavir. Laboratory data and clinical implications of ADRs were collected through electronic medical records. The ADRs were evaluated and cross checked by three independent pharmacists. Results : Totally, 28 patients were evaluated, and 15 ADRs were detected. Ribavirin was the most causative agent. Hematologic ADRs were the maximum reported, and nausea/vomiting was second ranked. Seven ADRs were scored as Grade 3 severity of ADRs, as per the CTCAE ver. 4.0; the causative drug was discontinued in 9 cases. Causality scores using WHO-UMC and Naranjo scale indicated that most of the ADR cases had a‘ possible’relationship. Conclusion : ADR patterns of the three drugs evaluated for MERS-CoV patients were mostly similar with the limited existing reports.
Abstract
Background : Treatment experiences with antiviral agents against MERS-CoV (Middle East Respiratory Syndrome Coronavirus) infection are limited, and there is lack of information regarding adverse drug reactions (ADRs) in this patient group. In 2015, we evaluated the ADRs of antiviral treatment against MERS-CoV infections in one tertiary teaching hospital in South Korea.
참고문헌 (17)
- "MERS 항바이러스제 치료지침", 대한감염학회, ~ (2015)
- American Society of Health-system Pharmacists, "AHFS Drug Information, 2015", ASHP, 620~790 (2015)
- Omrani AS, "Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study", Lancet Infect Dis, 14, pp.1090~1095 (2014)
- Chiou HE, "Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers", Chest, 128, pp.263~272 (2005)
- Knowles SR, "Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada", Clin Infect Dis, 37, pp.1139~1142 (2003)
- Muller MP, "Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome", Pharmacotherapy, 27, pp.494~503 (2007)
- Gara N, "What the infectious disease physician needs to know about pegylated interferon and ribavirin", Clin Infect Dis, 56, pp.1629~1636 (2013)
- "바이라미드 200mg", 일성신약, 제품설명서, ~
- "페가시스 주 180mcg 프로클릭", 로슈, 제품설명서, ~
- "페가시스프리필드 주 135mcg", 로슈, 제품설명서, ~
- "칼레트라정 200", 50mg
- "약물부작용보고평가 사례집", 한국의약품안전관리원, ~ (2013)
- Naranjo CA, "A method for estimating the probability of adverse drug reactions", Clin Pharmacol Ther, 30(2), pp.239~245 (1981)
- US. DEPARTMENT OF HEALTH AND HUMAN SERVICES, "Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", ~ (2009)
- 정용필, "Antiviral Treatment Guidelines for Middle East Respiratory Syndrome", Infection and Chemotherapy, 47(3), pp.212~222 (2015), 대한감염학회
- 최원석, "Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea", Infection and Chemotherapy, 48(2), pp.118~126 (2016), 대한감염학회
- Park SJ, "Evaluation of adverse drug reactions in medical intensive care units", Eur J Clin Pharmacol, 69, pp.119~131 (2013)